These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18564621)

  • 1. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy].
    Di Maio M; Gallo C; Perrone F
    Tumori; 2008; 94(2):suppl 14-22. PubMed ID: 18564621
    [No Abstract]   [Full Text] [Related]  

  • 2. [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects].
    Pradelli L; Eandi M
    Tumori; 2008; 94(2):suppl 26-32. PubMed ID: 18564623
    [No Abstract]   [Full Text] [Related]  

  • 3. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M; Awab A; Chaudhary L; Tfayli A
    J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
    [No Abstract]   [Full Text] [Related]  

  • 4. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5HT3-receptor antagonists as antiemetics in cancer.
    Drug Ther Bull; 2005 Aug; 43(8):57-62. PubMed ID: 16111085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy].
    Labianca R; Mandalà M; Clerici M
    Tumori; 2008; 94(2):suppl 23-5. PubMed ID: 18564622
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
    Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
    J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
    Vacirca J; Caruana D; Calcanes G; Mosier M; Boccia R; McBride A
    Future Oncol; 2018 Jun; 14(14):1387-1396. PubMed ID: 29421926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
    Grunberg SM; Koeller JM
    Expert Opin Pharmacother; 2003 Dec; 4(12):2297-303. PubMed ID: 14640928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
    Ishido K; Higuchi K; Azuma M; Sasaki T; Tanabe S; Katada C; Yano T; Wada T; Koizumi W;
    Anticancer Drugs; 2016 Oct; 27(9):884-90. PubMed ID: 27254283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin antagonists for nausea and vomiting.
    Gastroenterol Nurs; 2014; 37(2):184-6. PubMed ID: 24691090
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population.
    Tian W; Wang Z; Zhou J; Zhang S; Wang J; Chen Q; Huang C; Pan L; Zhang L; Huang J; Shen H; Lin T
    Med Oncol; 2011 Mar; 28(1):71-8. PubMed ID: 20049561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on anti-emetics for chemotherapy-induced emesis.
    Olver IN
    Intern Med J; 2005 Aug; 35(8):478-81. PubMed ID: 16176471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
    Yu Z; Liu W; Wang L; Liang H; Huang Y; Si X; Zhang H; Liu D; Zhang H
    Support Care Cancer; 2009 Jan; 17(1):99-102. PubMed ID: 18825421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.